# A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

> **NCT06614751** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Danatlas Pharmaceuticals Co., Ltd** · enrollment: 112 (estimated)

## Conditions studied

- Solid Cancers
- BRCA Mutation
- HRD Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Endometrial Cancer
- Gastric Cancer
- Advanced Cancer
- Metastatic Solid Tumors

## Interventions

- **DRUG:** DAT-2645 tablet
- **DRUG:** DAT-2645 tablet

## Key facts

- **NCT ID:** NCT06614751
- **Lead sponsor:** Danatlas Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614751, "A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06614751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*